Evidence map›Paper›PMID 41625348›Full record

ArticleIranian journal of medical sciences2026

A Novel

Hamed Esmaeil Lashgarian, Masumeh Jalalvand, Maryam Zand, Amirmasoud Jalalvand, Leila Abkhooie, Fatemeh Kazemisafa, Hamidreza Khodadadi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hamed Esmaeil LashgarianDepartment of Medical Genetics and Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Masumeh JalalvandDepartment of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Maryam ZandDepartment of Biotechnology and Molecular Medicine, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Amirmasoud JalalvandDepartment of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila AbkhooieDepartment of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Fatemeh KazemisafaClinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Hamidreza KhodadadiDepartment of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spastic paraplegia 50 (SPG50) is a rare autosomal recessive disorder caused by mutations in the

Indexed as

Adaptor Protein Complex 4ParaplegiaSpastic Paraplegia, HereditaryChildConsanguinityExome SequencingFemaleFrameshift MutationHumansIranMaleMolecular Docking SimulationPedigreeAdaptor Protein Complex 4Frameshift mutationHereditary spastic paraplegiaWhole exome sequencing

Identifiers

PMID41625348
PMCPMC12858432

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.